Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion

Ophthalmologica

Volumn 232, Issue 4, 2014, Pages 216-222

  Nghiem Buffet, Sylvia ^a,c   Fajnkuchen, Franck ^a,b   Buffet, Marc ^a   Ayrault, Sandrine ^a   Le Gloahec Lorcy, Anna ^a   Grenet, Typhaine ^a,b   Delahaye Mazza, Corinne ^a   Quentel, Gabriel ^a   Cohen, Salomon Y ^a  

^a Centre Ophtalmologique d'Imagerie et de Laser 11   (France)

^b Institut Arthur Vernes   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Anti VEGF therapy; Branch retinal vein occlusion; Central retinal vein occlusion; Dexamethasone implant; Macular edema; Ranibizumab; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL IMPLANT; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; VISUAL ACUITY; VITREOUS HEMORRHAGE; COMPLICATION; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; RETINAL VEIN OCCLUSION; TIME; TREATMENT OUTCOME; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84927913034     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000365639     Document Type: Article

References (47)

1. Yau JW, Lee P, Wong TY, Best J, Jenkins A: Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008; 38: 904-910
2. Mitchell P, Smith W, Chang A: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247
3. Klein R, Klein BE, Moss SE, Meuer SM: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-141
4. Rehak J, Rehak M: Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-131
5. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998; 47: 1953-1959
6. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791-799
7. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98: 271-282
8. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425-1433
9. Leopold IH: Nonsteroidal and steroidal antiinflammatory agents; in Sears ML, Tarkkanen A (eds): Surgical Pharmacology of the Eye. New York, Raven Press, 1985, pp 83-133
10. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114
11. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128
12. Williamson TH, ODonnell A: Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005; 139: 860-866
13. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317
14. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146
15. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460
16. Labriola LKM, Csaky K: Pharmacokinetics of anti-vascular endothelial growth factor pharmacological agents; in Das A, Friberg TR (eds): Therapy for Ocular Angiogenesis: Principles and Practice. Philadelphia, Lippincott, Williams &Wilkins, 2010, vol 1, pp 204-210
17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King LJ: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
18. Peer J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E: Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105: 412-416
19. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791-799
20. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU: Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-149
21. Ferrara DC, Koizumi H, Spaide RF: Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144: 864-871
22. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U: Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008; 92: 518-522
23. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM: Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007; 143: 601-606
24. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A: Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27: 1004-1012
25. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133
26. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049
27. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112
28. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602
29. Pece A, Isola V, Piermarocchi S, Calori G: Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2011; 95: 56-68
30. Karagiannis DA, Karampelas MD, Soumplis VM, Amariotakis C, Georgalas I, Kandarakis A: Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis). Can J Ophthalmol 2011; 46: 486-490
31. Kim M, Yu SY, Kim ES, Bae SH, Park JH, Yu HG, Kwak HW: Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. Ophthalmologica 2012; 227: 132-138
32. Mylonas G, Sacu S, Dunavoelgyi R, Matt G, Blum R, Buehl W, Pruente C, Schmidt-Erfurth U; Macula Study Group: Response of retinal sensitivity to ranibizumab treatment of macular edema after acute branch retinal vein occlusion. Retina 2013; 33: 1220-1226
33. Gallego-Pinazo R, Dolz-Marco R, Pardo-Lopez D, Martinez-Castillo S, Lleo-Perez A, Arevalo JF, Diaz-Llopis M: Ranibizumab for serous macular detachment in branch retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol 2013; 251: 9-14
34. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P: Ranibizumab for macular edema due to retinal vein occlusions: longterm follow-up in the HORIZON trial. Ophthalmology 2012; 119: 802-809
35. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306
36. Rouvas A, Petrou P, Vergados I, Pechtasides D, Liarakos V, Mitsopoulou M, Ladas I: Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1609-1616
37. Chang LK, Spaide RF, Klancnik JM, Sorenson J, Slakter JS, Freund KB, Yannuzzi LA, Tseng JJ, Klein R: Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 2011; 31: 821-828
38. Parodi MB, Iacono P, De Benedetto U, Cascavilla M, Bandello F: Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 2012; 28: 566-568
39. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion. Ophthalmologica 2013; 229: 21-25
40. Querques G, Lattanzio R, Querques L, Triolo G, Cascavilla ML, Cavallero E, Del Turco C, Casalino G, Bandello F: Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function. Retina 2014; 34: 330-341
41. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A: Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye 2013; 27: 65-71
42. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M, Haritoglou C: Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 2013; 27: 816-822
43. Merkoudis N, Granstam E: Treatment of macular edema associated with retinal vein occlusion using sustained-release dexamethasone implants in a clinical setting. Eur J Ophthalmol 2013; 23: 558-563
44. Dinah C, Nenova K, Pushpoth S, El-Ghrably I, Varma D, Talks SJ: Intravitreal dexamethasone for central retinal vein occlusion with low visual acuity: a retrospective study. Br J Ophthalmol 2013; 97: 796-797
45. Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, Parravano MC, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A: Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2014; 24: 1-9
46. Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH: Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-The SOLO study. Acta Ophthalmol 2013; 91:e340-e347
47. Querques G, Triolo G, Casalino G, Garcia-Arumi J, Badal J, Zapata M, Boixadera A, Castillo VM, Bandello F: Retinal venous occlusions: diagnosis and choice of treatments. Ophthalmic Res 2013; 49: 215-222